NEW YORK (GenomeWeb News) – Asuragen today announced it has granted Becton Dickinson the rights to incorporate its Armored RNA technology into BD's in vitro molecular diagnostic products.
Asuragen will develop and supply reagents for BD Diagnostics in Asuragen's cGMP manufacturing facility under the terms of the deal. Other details of the non-exclusive worldwide agreement were not disclosed.
Armored RNA was jointly invented and developed by Asuragen and Cenetron Diagnostics to create RNA and DNA standards for molecular diagnostic assays. The technology has been incorporated into most HIV and HCV commercially available diagnostic assays that measure viral load, Austin, Texas-based Asuragen said.